196 related articles for article (PubMed ID: 20980108)
1. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Machtay M; Bae K; Movsas B; Paulus R; Gore EM; Komaki R; Albain K; Sause WT; Curran WJ
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):425-34. PubMed ID: 20980108
[TBL] [Abstract][Full Text] [Related]
2. The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.
Lawrence YR; Paulus R; Langer C; Werner-Wasik M; Buyyounouski MK; Komaki R; Machtay M; Smith C; Axelrod RS; Wasserman T; Bradley JD; Movsas B
Lung Cancer; 2013 Jun; 80(3):298-305. PubMed ID: 23477890
[TBL] [Abstract][Full Text] [Related]
3. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
Palma DA; Senan S; Tsujino K; Barriger RB; Rengan R; Moreno M; Bradley JD; Kim TH; Ramella S; Marks LB; De Petris L; Stitt L; Rodrigues G
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):444-50. PubMed ID: 22682812
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
Ning MS; Tang L; Gomez DR; Xu T; Luo Y; Huo J; Mouhayar E; Liao Z
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):70-79. PubMed ID: 28816165
[TBL] [Abstract][Full Text] [Related]
5. A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients.
Oberije C; De Ruysscher D; Houben R; van de Heuvel M; Uyterlinde W; Deasy JO; Belderbos J; Dingemans AM; Rimner A; Din S; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):935-44. PubMed ID: 25936599
[TBL] [Abstract][Full Text] [Related]
6. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
Movsas B; Moughan J; Sarna L; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Wasserman T; Bruner DW
J Clin Oncol; 2009 Dec; 27(34):5816-22. PubMed ID: 19858383
[TBL] [Abstract][Full Text] [Related]
7. Definitive Chemoradiotherapy Results in Synchronous Oligometastatic Non-small Cell Lung Cancer Patients: Turkish Society for Radiation Oncology Group Study (TROD 10-003).
Duru Birgi S; Akgun Z; Hurmuz P; Akyurek S; Kaytan Saglam E; Yilmaz MT; Bakirarar B; Cengiz M
Am J Clin Oncol; 2022 Jan; 45(1):40-47. PubMed ID: 34857699
[TBL] [Abstract][Full Text] [Related]
8. Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.
Hatton MQF; Lawless CA; Faivre-Finn C; Landau D; Lester JF; Fenwick J; Simões R; McCartney E; Boyd KA; Haswell T; Shaw A; Paul J
BMJ Open; 2019 Jan; 9(1):e019903. PubMed ID: 30700475
[TBL] [Abstract][Full Text] [Related]
9. Variations in Initiation Dates of Chemotherapy and Radiation Therapy for Definitive Management of Inoperable Non-Small Cell Lung Cancer Are Associated With Decreases in Overall Survival.
Deek MP; Kim S; Beck R; Yegya-Raman N; Langenfeld J; Malhotra J; Mahmoud O; Aisner J; Jabbour SK
Clin Lung Cancer; 2018 Jul; 19(4):e381-e390. PubMed ID: 29752011
[TBL] [Abstract][Full Text] [Related]
10. Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies.
Zhao J; Xia Y; Kaminski J; Hao Z; Mott F; Campbell J; Sadek R; Kong FM
PLoS One; 2016; 11(6):e0157455. PubMed ID: 27300551
[TBL] [Abstract][Full Text] [Related]
11. The influence of gender, race, and marital status on survival in lung cancer patients: analysis of Radiation Therapy Oncology Group trials.
Siddiqui F; Bae K; Langer CJ; Coyne JC; Gamerman V; Komaki R; Choy H; Curran WJ; Watkins-Bruner D; Movsas B
J Thorac Oncol; 2010 May; 5(5):631-9. PubMed ID: 20432520
[TBL] [Abstract][Full Text] [Related]
12. Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors.
Friedes C; Iocolano M; Lee SH; Li B; Duan L; Levin WP; Cengel KA; Sun LL; Aggarwal C; Marmarelis ME; Doucette A; Cohen RB; Xiao Y; Langer CJ; Bradley J; Feigenberg SJ; Yegya-Raman N
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1435-1444. PubMed ID: 37866762
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model.
Geng C; Paganetti H; Grassberger C
Sci Rep; 2017 Oct; 7(1):13542. PubMed ID: 29051600
[TBL] [Abstract][Full Text] [Related]
14. Interpretable Machine Learning for Choosing Radiation Dose-volume Constraints on Cardio-pulmonary Substructures Associated with Overall Survival in NRG Oncology RTOG 0617.
Lee SH; Geng H; Arnold J; Caruana R; Fan Y; Rosen MA; Apte AP; Deasy JO; Bradley JD; Xiao Y
Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1270-1286. PubMed ID: 37343707
[TBL] [Abstract][Full Text] [Related]
15. Left Anterior Descending Coronary Artery Radiation Dose Association With All-Cause Mortality in NRG Oncology Trial RTOG 0617.
McKenzie E; Zhang S; Zakariaee R; Guthier CV; Hakimian B; Mirhadi A; Kamrava M; Padda SK; Lewis JH; Nikolova A; Mak RH; Atkins KM
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1138-1143. PubMed ID: 36436615
[TBL] [Abstract][Full Text] [Related]
16. Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer.
Feliciano J; Feigenberg S; Mehta M
Cancer J; 2013; 19(3):222-30. PubMed ID: 23708069
[TBL] [Abstract][Full Text] [Related]
17. Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Ito M; Niho S; Nihei K; Yoh K; Ohmatsu H; Ohe Y
BMC Cancer; 2012 Jan; 12():27. PubMed ID: 22260460
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"?
Ohri N
Front Oncol; 2017; 7():205. PubMed ID: 28983464
[TBL] [Abstract][Full Text] [Related]
19. Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC.
Scott JG; Sedor G; Scarborough JA; Kattan MW; Peacock J; Grass GD; Mellon EA; Thapa R; Schell M; Waller A; Poppen S; Andl G; Teer JK; Eschrich SA; Dilling TJ; Dalton WS; Harrison LB; Fox T; Torres-Roca JF
J Thorac Oncol; 2021 Mar; 16(3):428-438. PubMed ID: 33301984
[TBL] [Abstract][Full Text] [Related]
20. Early radiologic and metabolic tumour response assessment during combined chemo-radiotherapy for locally advanced NSCLC.
Tvilum M; Knap MM; Hoffmann L; Khalil AA; Appelt AL; Haraldsen A; Alber M; Grau C; Schmidt HH; Kandi M; Holt MI; Lutz CM; Møller DS
Clin Transl Radiat Oncol; 2024 Mar; 45():100737. PubMed ID: 38317680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
